ID   LGMN_HUMAN              Reviewed;         433 AA.
AC   Q99538; O00123; Q86TV2; Q86TV3; Q9BTY1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Legumain;
DE            EC=3.4.22.34;
DE   AltName: Full=Asparaginyl endopeptidase;
DE   AltName: Full=Protease, cysteine 1;
DE   Flags: Precursor;
GN   Name=LGMN; Synonyms=PRSC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=9065484; DOI=10.1074/jbc.272.12.8090;
RA   Chen J.-M., Dando P.M., Rawlings N.D., Brown M.A., Young N.E.,
RA   Stevens R.A.E., Hewitt E., Watts C., Barrett A.J.;
RT   "Cloning, isolation, and characterization of mammalian legumain, an
RT   asparaginyl endopeptidase.";
RL   J. Biol. Chem. 272:8090-8098(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RX   PubMed=8893817;
RA   Tanaka T., Inazawa J., Nakamura Y.;
RT   "Molecular cloning of a human cDNA encoding putative cysteine protease
RT   (PRSC1) and its chromosome assignment to 14q32.1.";
RL   Cytogenet. Cell Genet. 74:120-123(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Neuroblastoma, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ILE-18.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 18-24 AND 324-330, AND PROTEOLYTIC PROCESSING.
RX   PubMed=11085925; DOI=10.1042/bj3520327;
RA   Chen J.-M., Fortunato M., Barrett A.J.;
RT   "Activation of human prolegumain by cleavage at a C-terminal
RT   asparagine residue.";
RL   Biochem. J. 352:327-334(2000).
RN   [7]
RP   CHARACTERIZATION OF ACTIVITY ON ASPARTATE BONDS, AND AUTOCATALYTIC
RP   CLEAVAGE.
RX   PubMed=9821970; DOI=10.1016/S0014-5793(98)01281-2;
RA   Halfon S., Patel S., Vega F., Zurawski S., Zurawski G.;
RT   "Autocatalytic activation of human legumain at aspartic acid
RT   residues.";
RL   FEBS Lett. 438:114-118(1998).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-91 AND ASN-167.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 26-309, FUNCTION, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVE SITE, PROPEPTIDE,
RP   GLYCOSYLATION AT ASN-91; ASN-167; ASN-263 AND ASN-272, SUBUNIT,
RP   DOMAIN, MUTAGENESIS OF GLU-190, AND AUTOCATALYTIC PROCESSING.
RX   PubMed=23776206; DOI=10.1073/pnas.1300686110;
RA   Dall E., Brandstetter H.;
RT   "Mechanistic and structural studies on legumain explain its
RT   zymogenicity, distinct activation pathways, and regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:10940-10945(2013).
CC   -!- FUNCTION: Has a strict specificity for hydrolysis of asparaginyl
CC       bonds. Can also cleave aspartyl bonds slowly, especially under
CC       acidic conditions. Required for normal lysosomal protein
CC       degradation in renal proximal tubules. Required for normal
CC       degradation of internalized EGFR. Plays a role in the regulation
CC       of cell proliferation via its role in EGFR degradation (By
CC       similarity). May be involved in the processing of proteins for MHC
CC       class II antigen presentation in the lysosomal/endosomal system.
CC       {ECO:0000250, ECO:0000269|PubMed:23776206}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of proteins and small molecule
CC       substrates at -Asn-|-Xaa- bonds. {ECO:0000269|PubMed:23776206}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 5.5 for the free enzyme, and pH 6 in the presence
CC         of bound integrins. {ECO:0000269|PubMed:23776206};
CC   -!- SUBUNIT: Homodimer before autocatalytic removal of the propeptide
CC       (By similarity). Monomer after autocatalytic processing. May
CC       interact with integrins. {ECO:0000250,
CC       ECO:0000269|PubMed:23776206}.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q99538-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99538-2; Sequence=VSP_056454;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q99538-3; Sequence=VSP_056455, VSP_056456;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Particularly abundant in kidney,
CC       heart and placenta.
CC   -!- DOMAIN: In the zymogen form, the uncleaved propeptide blocks
CC       access to the active site. {ECO:0000269|PubMed:23776206}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:23776206}.
CC   -!- PTM: Activated by autocatalytic processing at pH 4.
CC       {ECO:0000269|PubMed:11085925}.
CC   -!- SIMILARITY: Belongs to the peptidase C13 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y09862; CAA70989.1; -; mRNA.
DR   EMBL; D55696; BAA09530.1; -; mRNA.
DR   EMBL; BX161380; CAD61872.1; -; mRNA.
DR   EMBL; BX161422; CAD61895.1; -; mRNA.
DR   EMBL; AL132987; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136332; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC003061; AAH03061.1; -; mRNA.
DR   CCDS; CCDS9904.1; -. [Q99538-1]
DR   RefSeq; NP_001008530.1; NM_001008530.2. [Q99538-1]
DR   RefSeq; NP_005597.3; NM_005606.6. [Q99538-1]
DR   RefSeq; XP_005267919.1; XM_005267862.3. [Q99538-2]
DR   RefSeq; XP_005267920.1; XM_005267863.3. [Q99538-3]
DR   RefSeq; XP_016876952.1; XM_017021463.1. [Q99538-1]
DR   RefSeq; XP_016876953.1; XM_017021464.1. [Q99538-1]
DR   RefSeq; XP_016876954.1; XM_017021465.1. [Q99538-1]
DR   RefSeq; XP_016876955.1; XM_017021466.1. [Q99538-2]
DR   RefSeq; XP_016876956.1; XM_017021467.1. [Q99538-3]
DR   UniGene; Hs.18069; -.
DR   PDB; 4AW9; X-ray; 2.20 A; A=26-309.
DR   PDB; 4AWA; X-ray; 2.50 A; A=26-309.
DR   PDB; 4AWB; X-ray; 2.70 A; A/B=26-309.
DR   PDB; 4FGU; X-ray; 3.90 A; A/B=18-433.
DR   PDB; 4N6N; X-ray; 1.87 A; A=26-303.
DR   PDB; 4N6O; X-ray; 1.80 A; A=26-303.
DR   PDB; 5LU8; X-ray; 1.95 A; A=26-288.
DR   PDB; 5LU9; X-ray; 2.27 A; A=26-288.
DR   PDB; 5LUA; X-ray; 2.00 A; A/B=26-287.
DR   PDB; 5LUB; X-ray; 2.10 A; A/B=26-287.
DR   PDBsum; 4AW9; -.
DR   PDBsum; 4AWA; -.
DR   PDBsum; 4AWB; -.
DR   PDBsum; 4FGU; -.
DR   PDBsum; 4N6N; -.
DR   PDBsum; 4N6O; -.
DR   PDBsum; 5LU8; -.
DR   PDBsum; 5LU9; -.
DR   PDBsum; 5LUA; -.
DR   PDBsum; 5LUB; -.
DR   ProteinModelPortal; Q99538; -.
DR   SMR; Q99538; -.
DR   BioGrid; 111624; 18.
DR   IntAct; Q99538; 9.
DR   MINT; MINT-4537529; -.
DR   STRING; 9606.ENSP00000334052; -.
DR   BindingDB; Q99538; -.
DR   ChEMBL; CHEMBL4244; -.
DR   GuidetoPHARMACOLOGY; 2380; -.
DR   MEROPS; C13.004; -.
DR   iPTMnet; Q99538; -.
DR   PhosphoSitePlus; Q99538; -.
DR   BioMuta; LGMN; -.
DR   DMDM; 2842759; -.
DR   EPD; Q99538; -.
DR   MaxQB; Q99538; -.
DR   PaxDb; Q99538; -.
DR   PeptideAtlas; Q99538; -.
DR   PRIDE; Q99538; -.
DR   DNASU; 5641; -.
DR   Ensembl; ENST00000334869; ENSP00000334052; ENSG00000100600. [Q99538-1]
DR   Ensembl; ENST00000393218; ENSP00000376911; ENSG00000100600. [Q99538-1]
DR   Ensembl; ENST00000555699; ENSP00000451861; ENSG00000100600. [Q99538-3]
DR   Ensembl; ENST00000557434; ENSP00000452572; ENSG00000100600. [Q99538-2]
DR   GeneID; 5641; -.
DR   KEGG; hsa:5641; -.
DR   UCSC; uc001yav.4; human. [Q99538-1]
DR   CTD; 5641; -.
DR   DisGeNET; 5641; -.
DR   GeneCards; LGMN; -.
DR   HGNC; HGNC:9472; LGMN.
DR   HPA; HPA000799; -.
DR   HPA; HPA001426; -.
DR   MIM; 602620; gene.
DR   neXtProt; NX_Q99538; -.
DR   OpenTargets; ENSG00000100600; -.
DR   PharmGKB; PA30354; -.
DR   eggNOG; KOG1348; Eukaryota.
DR   eggNOG; COG5206; LUCA.
DR   GeneTree; ENSGT00530000063391; -.
DR   HOGENOM; HOG000236335; -.
DR   HOVERGEN; HBG031304; -.
DR   InParanoid; Q99538; -.
DR   KO; K01369; -.
DR   OMA; DRIKLSM; -.
DR   OrthoDB; EOG091G08C5; -.
DR   PhylomeDB; Q99538; -.
DR   TreeFam; TF313403; -.
DR   BRENDA; 3.4.22.34; 2681.
DR   Reactome; R-HSA-1679131; Trafficking and processing of endosomal TLR.
DR   Reactome; R-HSA-196791; Vitamin D (calciferol) metabolism.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   SABIO-RK; Q99538; -.
DR   ChiTaRS; LGMN; human.
DR   GeneWiki; LGMN; -.
DR   GenomeRNAi; 5641; -.
DR   PMAP-CutDB; Q99538; -.
DR   PRO; PR:Q99538; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100600; -.
DR   CleanEx; HS_LGMN; -.
DR   ExpressionAtlas; Q99538; baseline and differential.
DR   Genevisible; Q99538; HS.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0036021; C:endolysosome lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IEA:Ensembl.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; ISS:UniProtKB.
DR   GO; GO:0008233; F:peptidase activity; IDA:MGI.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:1901185; P:negative regulation of ERBB signaling pathway; ISS:UniProtKB.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IGI:MGI.
DR   GO; GO:0006508; P:proteolysis; ISS:UniProtKB.
DR   GO; GO:0051603; P:proteolysis involved in cellular protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0032801; P:receptor catabolic process; ISS:UniProtKB.
DR   GO; GO:0003014; P:renal system process; ISS:UniProtKB.
DR   GO; GO:0010447; P:response to acidic pH; IEA:Ensembl.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006624; P:vacuolar protein processing; IBA:GO_Central.
DR   GO; GO:0042359; P:vitamin D metabolic process; TAS:Reactome.
DR   InterPro; IPR001096; Peptidase_C13.
DR   PANTHER; PTHR12000; PTHR12000; 1.
DR   Pfam; PF01650; Peptidase_C13; 1.
DR   PIRSF; PIRSF019663; Legumain; 1.
DR   PRINTS; PR00776; HEMOGLOBNASE.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Hydrolase;
KW   Lysosome; Polymorphism; Protease; Reference proteome; Signal;
KW   Thiol protease; Zymogen.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:11085925}.
FT   CHAIN        18    323       Legumain.
FT                                /FTId=PRO_0000026502.
FT   PROPEP      324    433
FT                                /FTId=PRO_0000026503.
FT   ACT_SITE    148    148       {ECO:0000305|PubMed:23776206}.
FT   ACT_SITE    189    189       Nucleophile.
FT                                {ECO:0000269|PubMed:23776206}.
FT   SITE        323    324       Cleavage; by autolysis.
FT   CARBOHYD     91     91       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23776206}.
FT   CARBOHYD    167    167       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23776206}.
FT   CARBOHYD    263    263       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:23776206}.
FT   CARBOHYD    272    272       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:23776206}.
FT   DISULFID    378    412       {ECO:0000250}.
FT   DISULFID    390    429       {ECO:0000250}.
FT   VAR_SEQ     341    397       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_056454.
FT   VAR_SEQ     341    372       ARHLIEKSVRKIVSLLAASEAEVEQLLSERAP -> DKIVH
FT                                GPRVPWSLLKSCLLEAFPSVSAPPTVC (in isoform
FT                                3). {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_056455.
FT   VAR_SEQ     373    433       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_056456.
FT   VARIANT      18     18       V -> I (in dbSNP:rs2236264).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_024588.
FT   MUTAGEN     190    190       E->K: Increases catalytic activity at pH
FT                                5.5. {ECO:0000269|PubMed:23776206}.
FT   MUTAGEN     323    323       N->D,Q,S: Loss of autoactivation.
FT   CONFLICT     31     31       V -> A (in Ref. 2; BAA09530).
FT                                {ECO:0000305}.
FT   STRAND       28     35       {ECO:0000244|PDB:4N6O}.
FT   HELIX        40     42       {ECO:0000244|PDB:4N6O}.
FT   HELIX        43     58       {ECO:0000244|PDB:4N6O}.
FT   HELIX        63     65       {ECO:0000244|PDB:4N6O}.
FT   STRAND       66     69       {ECO:0000244|PDB:4N6O}.
FT   STRAND       87     89       {ECO:0000244|PDB:4AW9}.
FT   HELIX       105    107       {ECO:0000244|PDB:4N6O}.
FT   HELIX       110    118       {ECO:0000244|PDB:4N6O}.
FT   TURN        121    126       {ECO:0000244|PDB:4N6O}.
FT   STRAND      140    146       {ECO:0000244|PDB:4N6O}.
FT   STRAND      153    155       {ECO:0000244|PDB:4N6O}.
FT   STRAND      157    162       {ECO:0000244|PDB:4N6O}.
FT   HELIX       163    175       {ECO:0000244|PDB:4N6O}.
FT   STRAND      180    186       {ECO:0000244|PDB:4N6O}.
FT   HELIX       191    194       {ECO:0000244|PDB:4N6O}.
FT   TURN        195    197       {ECO:0000244|PDB:4N6O}.
FT   STRAND      202    210       {ECO:0000244|PDB:4N6O}.
FT   STRAND      217    222       {ECO:0000244|PDB:4N6O}.
FT   TURN        223    226       {ECO:0000244|PDB:4N6O}.
FT   STRAND      227    231       {ECO:0000244|PDB:4N6O}.
FT   HELIX       232    243       {ECO:0000244|PDB:4N6O}.
FT   TURN        246    248       {ECO:0000244|PDB:4N6O}.
FT   HELIX       251    261       {ECO:0000244|PDB:4N6O}.
FT   STRAND      268    271       {ECO:0000244|PDB:4N6O}.
FT   HELIX       273    277       {ECO:0000244|PDB:4N6O}.
FT   HELIX       281    284       {ECO:0000244|PDB:4N6O}.
SQ   SEQUENCE   433 AA;  49411 MW;  081AD2D0D584E72A CRC64;
     MVWKVAVFLS VALGIGAVPI DDPEDGGKHW VVIVAGSNGW YNYRHQADAC HAYQIIHRNG
     IPDEQIVVMM YDDIAYSEDN PTPGIVINRP NGTDVYQGVP KDYTGEDVTP QNFLAVLRGD
     AEAVKGIGSG KVLKSGPQDH VFIYFTDHGS TGILVFPNED LHVKDLNETI HYMYKHKMYR
     KMVFYIEACE SGSMMNHLPD NINVYATTAA NPRESSYACY YDEKRSTYLG DWYSVNWMED
     SDVEDLTKET LHKQYHLVKS HTNTSHVMQY GNKTISTMKV MQFQGMKRKA SSPVPLPPVT
     HLDLTPSPDV PLTIMKRKLM NTNDLEESRQ LTEEIQRHLD ARHLIEKSVR KIVSLLAASE
     AEVEQLLSER APLTGHSCYP EALLHFRTHC FNWHSPTYEY ALRHLYVLVN LCEKPYPLHR
     IKLSMDHVCL GHY
//
